<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04489914</url>
  </required_header>
  <id_info>
    <org_study_id>TAVI-STAR</org_study_id>
    <nct_id>NCT04489914</nct_id>
  </id_info>
  <brief_title>Observational Study on the Application of High-Flow Therapy After Percutaneous Transfemoral Aortic Valve Replacement</brief_title>
  <official_title>Observational Study on the Application of High-Flow Therapy in the Postinterventional Follow-up Care of Patients With Percutaneous Interventional Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drägerwerk AG &amp; Co. KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Drägerwerk AG &amp; Co. KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous catheter-assisted valve replacement in aortic position (TAVI) for patients with
      high perioperative risk has become a standard method in recent years. In addition to the
      detection of bleeding and cardiac rhythm complications, follow-up care is mainly focused on
      the monitoring of respiratory parameters after an operation under intubation anesthesia or
      deep analgosedation. In addition to normal oxygen therapy, non-invasive ventilation and, in
      case of weaning failure, renewed tracheal intubation in the first 24 h after TAVI have been
      considered. High flow oxygen therapy (HFOT) now provides a good opportunity to treat patients
      with a warmed and humidified air-oxygen mixture and to independently control the oxygen
      content in the inhaled air and the flow in the pharyngeal area.

      The aim of the Study is to investigate the Change in oxygenation after high-flow oxygen
      therapy as a measure of weaning success in postinterventional patients after TAVI.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Horovitz index</measure>
    <time_frame>24 hours</time_frame>
    <description>The Gradient of paO2/FiO2 will be determined after TAVI via blood gas analysis</description>
  </primary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Transcatheter Aortic Valve Replacement</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-Flow Oxygen Therapy</intervention_name>
    <description>high-flow oxygen therapy after percutaneous transfemoral aortic valve replacement</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        University hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High-flow oxygen therapy after TAVI

        Exclusion Criteria:

          -  patients without consent

          -  age &lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Graf, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Schleswig-Holstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna Heering, Dr</last_name>
    <phone>+49 451 882</phone>
    <phone_ext>4020</phone_ext>
    <email>johanna.heering@draeger.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 24, 2020</study_first_submitted>
  <study_first_submitted_qc>July 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

